Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Pharmaceuticals Inc.

www.alnylam.com

Latest From Alnylam Pharmaceuticals Inc.

From US To EU: Young Biotechs Going It Alone

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

Strategy Rare Diseases

Roche Secures Dicerna RNAi Deal For Hepatitis B

Roche has paid $200m up front to get its hands on Dicerna’s RNAi-based drug for chronic hepatitis B in a deal that could be worth around $1.5bn.

Commercial Companies

EU Accelerated Assessment Tracker

The outcomes of six requests for accelerated assessment that companies have made for their planned marketing authorization applications in the EU are still unknown.

Europe Drug Review

Last Two Of Three Big Inclisiran Studies Boosts The Medicines Co.

Filings for the twice-yearly anti-PCSK9 injection under a partnership with Alnylam are on track, including a fourth quarter submission in the US. Detailed ORION-9 and ORION-10 data will be presented at AHA in November.

Clinical Trials Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Alnylam Holding Co.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alnylam Pharmaceuticals Inc.
  • Senior Management
  • John M Maraganore, PhD, CEO
    Jeff S Poulton, EVP, CFO
    Pushkal Garg, MD, CMO
    Barry Greene, Pres.
    Yvonne Greenstreet, COO
    Kevin Fitzgerald, PhD, SVP, CSO
  • Contact Info
  • Alnylam Pharmaceuticals Inc.
    Phone: (617) 551-8200
    300 Third St., 3rd. Fl.
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register